evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

48 questions · 48 findings · 16 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 12 · 25%GRADE not reported 1 · 2.1%Very low 12 · 25%Low 13 · 27.1%Moderate 7 · 14.6%High 3 · 6.3%

Summary of findings table ‐ Convalescent plasma vs human immunoglobulin

All‐cause mortality at up to day 28 · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 compared with human immunoglobulin (low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

All‐cause mortality at up to day 28 · outpatients withmild disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs standard plasma

All‐cause mortality at up to day 28 · outpatients withmild disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs standard plasma

All‐cause mortality at up to day 28 · individuals with moderate to severe disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).

1 finding from 1 review

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Intervention not reported

28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)

The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality at day 45 · non‐hospitalised adults with mild COVID‐19

The intervention showed no clear difference in all‐cause mortality at day 45 (low certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).

1 finding from 1 review

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Methylprednisolone vs dexamethasone

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…

It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).

1 finding from 1 review